Portuguese 
English 
Spanish 
3 min of reading 
0 comments 
Discover How the Venom of This Reptile Native to North America Inspired the Development of Innovative Drugs for Diabetes and Obesity
The Gila Monster, scientifically known as Heloderma suspectum, is a lizard native to North America that, despite its peculiar appearance and venomous bite, has played a crucial role in the development of medications for type 2 diabetes.
This reptile, which moves slowly through the deserts, is responsible for one of the most significant medical discoveries in recent years, which promises to transform the treatment of diabetes and obesity.
In its venom, researchers discovered an enzyme that inspired the development of drugs that enhance the activity of the GLP-1 receptor, such as Ozempic, Wegovy, and Mounjaro.
-
The invisible flaw that protects banks, passwords, and messages may be numbered after a quantum experiment transforms imperfect randomness into numbers impossible to predict.
-
China has ceased to be just a factory for cheap products and now challenges health giants: Chinese laboratories are advancing in medicines, while other countries recalculate their medical dependence.
-
Scientists from the USA have buried two seismometers in Antarctica at a depth of about 2.4 km under the ice, the deepest ever recorded, and are using the IceCube observatory structure to enhance earthquake monitoring, tsunami alerts, and nuclear test surveillance.
-
A photo taken by chance in the interior of Australia rediscovered a plant that the entire world had considered extinct for sixty years.
These drugs have shown promising results in combating type 2 diabetes and obesity.
The Importance of Gila Monster Venom
The venom of the Gila Monster evolved to immobilize its prey, allowing this lizard to survive with an extremely slow metabolism.
According to the University of Queensland, these lizards can live for up to a year on just six meals. The hormone identified in the venom, called exendin-4, bears similarities to human GLP-1, which regulates blood sugar levels.
The crucial difference between exendin-4 and GLP-1 is that the former remains in the body longer, providing a more lasting effect on glucose regulation.
This finding enabled the development of drugs that act as agonists of the GLP-1 receptor, leading to a revolution in diabetes treatment.
From Toxic to Therapeutic: The Evolution of Drugs
The first clinical application of exendin-4 resulted in the medication Byetta (exenatide), aimed at treating type 2 diabetes. This drug was fundamental in creating other more effective and long-lasting compounds, such as semaglutide, which is the active ingredient in Ozempic and Wegovy.
Professor Kini, a specialist in toxins, emphasizes that a small modification in the molecular structure can significantly enhance the effectiveness and duration of the therapeutic effect.
In addition to the venom of the Gila Monster, the study of toxins as medical treatment has led to advances in various fields. For example, the venom of the Brazilian snake Bothrops jararaca resulted in essential medications for blood pressure control, like captopril and enalapril.
The Potential of Toxins in Modern Medicine
Researchers around the world have been exploring toxins from various species to develop new treatments.
Venom from cone snails has been modified to treat chronic pain, while leech saliva has produced anticoagulants that reduce the risk of embolism.
The principle behind these innovations is the same: understanding how toxins affect the body can lead to new therapies.
Professor Kini is currently investigating snake venoms and mosquito saliva with the aim of creating medications that can prevent heart damage after a heart attack.
He points out that often, variations in one or two amino acids in toxins can trigger specific physiological effects, making it possible to transform them into effective treatments.
The Promising Future of Toxins in Medicine
The experience with the Gila Monster illustrates the potential of molecular biology and pharmacology in creating new drugs.
Despite the challenges of funding and the time required to turn laboratory discoveries into marketable treatments, Kini believes that the results justify the efforts.
“The future may hold new surprises for us”, says Kini. “
We can still find effective compounds in other venoms or develop synthetic versions that address diseases in new ways.”
Ongoing research on toxins not only reveals new therapeutic possibilities but also highlights the importance of exploring biodiversity for significant medical advancements.
SOURCE: ESTADODEMINAS
-
-
2 people reacted to this.